Back to mobile site

Gilead Sciences (GILD) Misses Q3 EPS by 8c, Revises 2014 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. APGE
6. MU
7. HOOD
8. DFTX
9. USO
10. MSFT

October 28, 2014 4:08 PM EDT

Gilead Sciences (NASDAQ: GILD) reported Q3 EPS of $1.84, $0.08 worse than the analyst estimate of $1.92. Revenue for the quarter came in at $6.04 billion versus the consensus estimate of $5.99 billion.

Revised 2014 Full Year Guidance

Gilead updated its full year 2014 guidance, which it initially provided on February 4, 2014, updated on July 23, 2014, and further revised on October 28, 2014:

(In millions, except percentages and per share amounts)

Initially ProvidedFebruary 4, 2014;Reiterated April 22,2014

UpdatedJuly 23, 2014

Provided onOctober 28, 2014

Net Product Sales $11,300 - $11,500 $21,000 - $23,000 $22,000 - $23,000
Non-GAAP*
Product Gross Margin 75% - 77% 85% - 88% 86% - 88%
R&D $2,200 - $2,300 $2,300 - $2,400 $2,300 - $2,400
SG&A $2,100 - $2,200 $2,300 - $2,400 $2,700 - $2,800 **
Effective Tax Rate 28% - 29% 17.5% - 20.5% 17.5% - 19.5%
Diluted EPS Impact of Acquisition-Related, Restructuring and Stock-Based Compensation Expenses $0.63 - $0.66 $0.63 - $0.66 $0.63 - $0.66

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance, Hot Earnings, Hot Guidance

Related Entities

Earnings, Definitive Agreement